Xtl Biopharmaceuticals (XTLB) Interest Coverage Ratio (2009 - 2024)
Xtl Biopharmaceuticals (XTLB) posted quarterly Interest Coverage Ratio of 7.52 for Q4 2024, up 64.26% on a QoQ basis from 21.03 in Q3 2024.
Xtl Biopharmaceuticals (XTLB) Interest Coverage Ratio (2009 - 2024) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Interest Coverage Ratio for 13 consecutive years, with 7.52 the latest figure, recorded in Q4 2024.
- Quarterly Interest Coverage Ratio changed N/A year-over-year to 7.52 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 4.78 (down 153.16% YoY) and the FY2025 annual result came in at 6.35, up 8.29% from the prior year.
- Interest Coverage Ratio improved to 7.52 in Q4 2024 per XTLB's latest filing, from 21.03 in the prior quarter.
- Over the last five years, Interest Coverage Ratio for XTLB reached as high as 59.31 in Q2 2024 and fell as low as 553.0 in Q3 2022.
- A 3-year average of 50.7 and a median of 1.21 in 2024 frame the typical range for Interest Coverage Ratio.
- The largest YoY upside for Interest Coverage Ratio was 1064.32% in 2024 against a maximum downside of 208.94% in 2024.
- Year by year, Interest Coverage Ratio stood at 553.0 in 2022, then soared by 93.68% to 34.96 in 2023, then soared by 78.5% to 7.52 in 2024.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 7.52, 21.03, and 59.31 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -157.58 |
| 4 | BeOne Medicines | 471.65 Bn | 466.85 Bn | 1.35 Bn | 7.60 |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.09 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.74 Bn | 50.56 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.48 Bn | 37.48 Bn | - | -0.38 |
| 10 | Xtl Biopharmaceuticals | 2.58 Bn | 2.58 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -7.52 |
| Sep 30, 2024 | -21.03 |
| Jun 30, 2024 | 59.31 |
| Mar 31, 2024 | -10.94 |
| Sep 30, 2023 | -34.96 |
| Jun 30, 2023 | 5.09 |
| Mar 31, 2023 | 10.04 |
| Sep 30, 2022 | -553.00 |
| Jun 30, 2022 | 18.36 |
| Mar 31, 2022 | 27.67 |
| Dec 31, 2018 | -3.40 |
| Sep 30, 2018 | 477.00 |
| Jun 30, 2018 | -8.36 |
| Mar 31, 2018 | -33.00 |
| Dec 31, 2017 | -3.20 |
| Sep 30, 2017 | 0.15 |
| Jun 30, 2017 | -1.15 |
| Mar 31, 2017 | 0.49 |
| Dec 31, 2016 | -91.77 |
| Sep 30, 2016 | 300.00 |